Effects of induction of multi-drug resistance on accumulation of 99mTc-sestamibi in vitro

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1833-1839

  Bender, Hans ^a   Friedrich, Eric ^a   Zamora, Paul O ^b   Guhlke, Stefan ^a   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

^b RhoMed Inc   (United States)

Author keywords

High grade glioma; Multidrug resistance; Ovarian carcinoma; Prostate carcinoma; Sestamibi

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; VINCRISTINE;

ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL DIVISION; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; GLIOMA; HUMANS; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TECHNETIUM TC 99M SESTAMIBI; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0030906337     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pastan I, Gottesmann M: Multiple-drug resistance in human cancer. N Eng J Med. 316: 1388-1393, 1987.
2. Bradley G, Juranka PF, Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
3. Riordan JR, Ling V: Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28: 51-75, 1985.
4. Juranka PF, Zastawny RL, Ling V: P-glycoprotein: multi-drug-resistance and a superfamily of membrane-associated transport proteins. Faseb J 3: 2583-2592, 1989.
5. Pearce H L Safa AR Bach NJ Winter MA Cirtain MC Beck WT: Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci (USA) 1989 86: 5128-5132, 1989.
6. Bell D R Gerlach JH Kartner N Buick RN Ling V: Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol 3: 311-315, 1985.
7. Volm M Mattern J Efferth T: P-glycoprotein as marker for multidrug-resistance in tumors and normal tissues. Tumordiagn u Ther 1990; 11: 189-197, 1990.
8. Verrelle P, Meissonnier F, Fonck Y: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83: 111-116, 1991.
9. Cole SPC, Bhardwaj G, Gerlach JH, Mackei JE, Grant CE et al: Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science 255: 1650-1654, 1992.
10. Izquierdo MA, Shoemaker RH, Flans MJ, et al: Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 65: 230-237, 1996.
11. Goldstein LJ, Fojo AT, Ueda K: Expression of the multidrug resistance MDR1 gene in neuroblastoma. J Clin Oncol 8: 128-136, 1990.
12. Ford JM., Bruggemann EP, Pastan I et al: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50: 1748-1756, 1990.
13. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
14. Piwnika-Worms D, Holman BL: Noncardiac application of hexakis (alkylisonitrile) technetium-99m complexes. J Nucl Med 31: 1166-1167, 1990.
15. Wackers FJ Berman DS Maddahi J et al: Technetium-99m hexakis 2-methoxyisobutylisonitrile: human biodistribution dosimetry safety and preliminary comparison to thallium-201 for myocardial perfusion imaging . J Nucl Med 14: 301-311, 1989.
16. Hassan I M Sahweil A Constantinides C: Uptake and kinetics of Tc-99m-hexakis 2-metoxyisobutyl isonitrile in benign and malignant lesions of the lungs. Clin Nucl Med 1989; 14: 333-340, 1989.
17. Caner B Kitapei M Unlu M: Tc-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with Tc-99m-MDP. J Nucl Med 1992; 33: 319-324, 1992.
18. Kao CH, Wang SJ, Liu TJ: The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 21: 432-436, 1994.
19. Moretti JL, Azaloux H, Boisseron D et al: Primary breast cancer imaging with technetium-99m sestamibi and its relation with Pglycoprotein Overexpression. Eur J Nucl Med 23: 980-986, 1996.
20. Palmcdo H, Grünwald F, Bender H et al: Scintimammography with technetium-99m methoxyisobutylisonitrilc: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 23: 940-946, 1996.
21. Piwnica-Worms D, Chiu ML, Budding M et al: Functional imaging of multidrug-resistance P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984, 1993.
22. Cordobes MD, Starzek A, Delmon-Moingeon L et al: Technetium-99mSestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 37: 286-289, 1996.
23. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D: Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 35: 510-515, 1994.
24. Sugawara I, Satake S, Watanabc M et al: Tumor imaging of multidrug-resistant cancers with organotechnetium complex. Tumor Targeting 2: 224-229, 1996.
25. Mosmann T: Rapid colorimetric assay for cellular growth and survival; application to proliferation and cytotoxic assays. J Immunol Meth 65: 5563-5565, 1983.
26. Futscher BW, Abbaszadegen MR, Domann F and Dalton WS: Analysis of MRP mRNA in mitochantrone-selected multidrug-resistance human tumor cells. Biochem Pharmacol 47: 1601-1604, 1994.
27. Flens MJ, Isquierdo MA, Scheffer GL et al: Immunochemical detection of MRP in human multi-drug resistant tumor cells by monoclonal antibodies. Cancer Res 54: 4557-4563, 1994.
28. Scheper RJ, Broxterman HJ, Scheper GL et al: Overexpression of a 110 kD vesicular protein in non-P-glycoprotein mediated multidrug-resistance. Cancer Res 53: 1475-1479, 199).
29. Zaman GJR, Flens MJ, van Leusden MR et al: The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump. Proc Natl Acad Sci (USA) 91: 8822-8826, 1994.